Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer
- PMID: 23264661
- DOI: 10.1177/1049909112470020
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer
Abstract
A new once-a-day fentanyl citrate transdermal patch was developed in Japan. We retrospectively investigated analgesic and adverse effects of this drug in 24 patients with lung cancer. All patients were started on this patch by switching from an oral opioid. The mean pain score before switching was 2.45 (0-5); 48 hours after switching, 15 of the 24 patients showed a decreased pain score and the mean score (2.00) was significantly lower than that before switching. Of the 16 patients who had adverse effects of oral opioids, 7 patients showed improvement in their symptoms after switching. Two patients showed adverse effects of the drug but their symptoms were mild, and no patient required dose decrease. This new transdermal patch could be a useful treatment option for cancer pain.
Keywords: analgesic effect; face scale; fentanyl citrate; lung cancer; oral opioid; transdermal fentanyl.
Similar articles
-
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.Support Care Cancer. 2016 Mar;24(3):1053-9. doi: 10.1007/s00520-015-2880-9. Epub 2015 Aug 7. Support Care Cancer. 2016. PMID: 26248654
-
Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.Support Care Cancer. 2006 May;14(5):400-7. doi: 10.1007/s00520-005-0918-0. Epub 2006 Feb 17. Support Care Cancer. 2006. PMID: 16485087
-
Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.Palliat Med. 2001 Jul;15(4):309-21. doi: 10.1191/026921601678320296. Palliat Med. 2001. PMID: 12054148
-
Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.Drug Saf. 2003;26(13):951-73. doi: 10.2165/00002018-200326130-00004. Drug Saf. 2003. PMID: 14583070 Review.
-
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.Drugs. 1997 Jan;53(1):109-38. doi: 10.2165/00003495-199753010-00011. Drugs. 1997. PMID: 9010652 Review.
Cited by
-
Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.Clin Drug Investig. 2014 Jul;34(7):501-11. doi: 10.1007/s40261-014-0204-3. Clin Drug Investig. 2014. PMID: 24906437 Free PMC article. Clinical Trial.
-
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.Support Care Cancer. 2016 Mar;24(3):1053-9. doi: 10.1007/s00520-015-2880-9. Epub 2015 Aug 7. Support Care Cancer. 2016. PMID: 26248654
-
Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain.BMC Palliat Care. 2014 Oct 8;13:46. doi: 10.1186/1472-684X-13-46. eCollection 2014. BMC Palliat Care. 2014. PMID: 25313295 Free PMC article.
-
Long-term use of a once-a-day fentanyl citrate transdermal patch in lung cancer patients.Oncol Lett. 2015 May;9(5):2105-2108. doi: 10.3892/ol.2015.3022. Epub 2015 Mar 9. Oncol Lett. 2015. PMID: 26137021 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources